Butterfly Learnings Secures ₹65 Crore in Pre-Series B Funding
Butterfly Learnings has raised ₹65 crore in a Pre-Series B round as it prepares for a wider expansion of its paediatric neurodevelopmental healthcare network.
The round was led by Inflexor Ventures, while existing investors Enzia Ventures, Insitor Impact Asia Fund and IIMA Ventures also participated. The latest investment gives the company additional resources to build out a model that combines physical therapy centres with diagnostics, digital tools, inclusive education and technology-supported interventions.
Founded in 2021 by Dr Sonam Kothari and Dr Abhishek Sen, Butterfly Learnings focuses on children requiring developmental and behavioural support, including those with autism, ADHD and learning disabilities.
Where Will Butterfly Learnings Use the New Funding?
A major part of the new capital is expected to support geographical expansion. Butterfly Learnings plans to extend its centre network further across India and deepen its presence beyond its existing Maharashtra base.
The company also intends to invest in technology and AI capabilities as it attempts to standardise and scale care across a larger network. Other priorities include therapist training, stronger partnerships with hospitals and paediatricians, and wider access to inclusive education.
Recent reports indicate that Butterfly Learnings has grown to around 90 centres across 22 cities, supported by more than 250 trained therapists.
That expansion is significant because behavioural and developmental healthcare is difficult to scale through physical infrastructure alone. Growth depends not simply on opening centres, but also on recruiting and training qualified professionals while maintaining consistent clinical standards.
Get SET Early Becomes an Important Part of Expansion
Another focus of the funding is Get SET Early, Butterfly Learnings' autism screening solution.
The eye-tracking-based screening technology is designed for early autism risk assessment and has received approval from India's Central Drugs Standard Control Organisation (CDSCO). Butterfly Learnings plans to expand its deployment through hospitals and paediatricians rather than limiting access to its own centres.
The approach could help the company establish a presence earlier in a child's care journey. Screening can potentially connect families with appropriate clinical evaluation and intervention sooner, although screening itself is not a substitute for comprehensive professional diagnosis.
From Therapy Centres to a Broader Care Ecosystem
Butterfly Learnings' strategy increasingly extends beyond operating therapy centres.
Its platform spans clinical therapy, diagnostics, inclusive schooling, digital therapeutics and technology-enabled interventions. Services are designed for children with developmental and behavioural needs, with the broader objective of creating a more integrated support system for families.
The company's expansion follows earlier institutional backing. In April 2024, Butterfly Learnings raised ₹32 crore in a Series A round led by Insitor Impact Asia Fund II and Enzia Ventures, with participation from IIMA Ventures, Foundation Botnar, 9Unicorns and Venture Catalysts.
Its earlier funding was directed toward expanding technology-enabled therapy programmes and increasing access to developmental and behavioural healthcare.
Why This Funding Matters
The ₹65 crore round highlights growing investor interest in specialised healthcare models addressing areas that have traditionally faced shortages of trained professionals and organised service providers.
Neurodevelopmental care is particularly challenging to scale because quality can depend heavily on therapist expertise, continuity of treatment, personalised intervention and coordination with families.
For Butterfly Learnings, therefore, expansion presents two opportunities at the same time: reaching more families and creating a larger, more structured network of specialised care.
Technology could play an important role in that process. Digital systems can help track progress, standardise workflows and support clinicians across multiple locations. Screening technologies may also improve access to early assessment.
But technology cannot entirely replace trained healthcare professionals, particularly in developmental and behavioural care where individual circumstances differ substantially.
The Bigger Challenge: Scaling Without Diluting Quality
Butterfly Learnings' next stage will test whether a specialised paediatric care model can grow rapidly while preserving clinical consistency.
Opening additional centres is relatively visible evidence of expansion. Maintaining therapist quality, measuring patient outcomes and ensuring that services remain accessible to families are harder benchmarks.
The company's investment in therapist training could therefore prove just as important as its physical expansion.
There is also the affordability question. Much developmental therapy in India continues to involve substantial out-of-pocket spending by families. Wider centre availability can improve geographical access, but sustainable scale will also depend on whether families across different income groups can consistently afford long-term intervention.
Balanced Analysis
The new investment gives Butterfly Learnings a stronger financial base to expand in a healthcare category with considerable unmet demand. Its combination of therapy centres, early screening, inclusive education and digital infrastructure offers an opportunity to create a more connected neurodevelopmental care pathway.
At the same time, funding and rapid centre expansion do not automatically guarantee improved healthcare outcomes. Success will ultimately depend on clinical quality, therapist availability, affordability, measurable patient progress and the company's ability to maintain consistent standards as its network becomes larger.
If Butterfly Learnings can balance these factors, its expansion could demonstrate how specialised healthcare networks can use technology and physical infrastructure together to improve access to neurodevelopmental services in India.
The ₹65 crore round therefore represents more than another healthtech fundraising announcement. It is also a test of whether organised, technology-supported neurodivergent care can be scaled nationally without losing the personalised approach such care requires.
This article is based on reporting published by Inc42.
